Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study
PaperCitations, authors & open-access status
Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 38 citations, 2021 year and hybrid oa status.
38
Citations
2021
Year
hybrid
OA Status